… GlaxoSmithKline was evaluated for its ability to protect nonhuman primates against SARS-CoV-2
challenge in advance of clinical trials. Although SARS-CoV-2 mRNA- and adenovirus-…

… ) of the SARS-CoV-2 S … in non-human primates (NHPs) and found that it could also induce
neutralizing antibodies and, most importantly, accelerate the viral clearance upon SARS-CoV-…

… immunity against SARS-CoV-2 in non-human primates. … effective subunit vaccine against
SARS-CoV-2 would represent an … for use in candidate subunit SARS-CoV-2 vaccines; however, …

… We show that intramuscular injection of LION/repRNA-CoV2S elicits robust anti-SARS-CoV-2 …
in nonhuman primates elicited antibody responses that potently neutralized SARS-CoV-2. …

… carry many mutations that result in the low- or noneffectiveness of the Alum/RBD-Fc and
the first-generation COVID-19 vaccines, our results suggest that RBD of the original SARS-CoV-…

… nonhuman primates … nonhuman primates were challenged at 10 weeks after the last
vaccination with GX-19, they had reduced viral loads in contrast to non-vaccinated primates as a …

… The nonhuman primate (NHP) model of SARS-CoV-2 … vaccine encoding the prefusion-stabilized
SARS-CoV-2 spike (S-2P) … following SARS-CoV-2 challenge in vaccinated animals and …

… By using a non-human primate (NHP) model of SARS-CoV-2 respiratory infection this study
aimed to analyze the related intestinal immune cell changes and to assess whether these …

… were replaced with a chimeric SARS-CoV-2 spike harboring the cytoplasmic tail of the
RSV F protein. MV-014-212 was attenuated and immunogenic in nonhuman primates (NHPs), …

… clinical trials, intervention experiments with non-human primates (NHPs) are appropriate
for … against SARS-CoV-2 infection are still obscured. Challenging macaque with SARS-CoV-2 …